PT-141 / Bremelanotide

10mg Vial

29 August 2026Updated 29 August 2026

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for PT-141 / Bremelanotide.

Create free account Member login

Full range of benefits for PT-141 / Bremelanotide

May increase sexual desire in premenopausal women with HSDD

Can improve sexual arousal and responsivity in some patients

Rapid onset of action (commonly within 30–60 minutes)

On‑demand, single‑dose subcutaneous administration

Acts centrally via melanocortin (MC4R) pathways

Non‑hormonal mechanism—alternative to estrogen/testosterone

Shown efficacy in randomized controlled trials

May reduce distress associated with low sexual desire

Does not require daily dosing for many patients

Option when hormonal therapy is contraindicated or undesired

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 12 known interactions

Synergistic(3)Compatible(3)Monitor(3)Avoid(3)

Works exceptionally well with this peptide

PDE5 inhibitors (sildenafil, tadalafil)

Central melanocortin agonism from bremelanotide combined with peripheral vasodilation from PDE5 inhibitors can produce additive improvements in sexual response and erection quality, though cardiovascular status should be considered.

Testosterone (testosterone replacement therapy)

Testosterone replacement can enhance peripheral and endocrine drivers of libido and may act complementarily with bremelanotide's central mechanism to improve sexual desire in appropriately selected hypogonadal patients.

Bupropion

Bupropion's pro-sexual effects through dopaminergic/noradrenergic modulation can complement bremelanotide's central melanocortin-mediated action to improve sexual desire and arousal with no major known pharmacokinetic interactions.

All interaction categories

Synergistic (3)

PDE5 inhibitors (sildenafil, tadalafil): Central melanocortin agonism from bremelanotide combined with peripheral vasodilation from PDE5 inhibitors can produce additive improvements in sexual response and erection quality, though cardiovascular status should be considered.
Testosterone (testosterone replacement therapy): Testosterone replacement can enhance peripheral and endocrine drivers of libido and may act complementarily with bremelanotide's central mechanism to improve sexual desire in appropriately selected hypogonadal patients.
Bupropion: Bupropion's pro-sexual effects through dopaminergic/noradrenergic modulation can complement bremelanotide's central melanocortin-mediated action to improve sexual desire and arousal with no major known pharmacokinetic interactions.

Compatible (3)

Selective serotonin reuptake inhibitors (SSRIs, e.g., sertraline, fluoxetine): No established pharmacokinetic interaction exists and bremelanotide may be used to address SSRI-associated sexual dysfunction without routine dose adjustment of the SSRI.
Combined oral contraceptives (estrogen/progestin): Hormonal contraceptives have no known effect on bremelanotide pharmacodynamics or dosing, making co-administration clinically acceptable.
Topical/local vaginal estrogen (e.g., estradiol cream): Local estrogen therapies for genitourinary symptoms of menopause have a neutral co-administration profile with bremelanotide and do not require adjustment.

Monitor (3)

Antihypertensive agents (beta‑blockers, ACE inhibitors, ARBs): Bremelanotide can cause transient increases in blood pressure and decreases in heart rate, so blood pressure and clinical response to antihypertensives should be monitored and doses adjusted if needed.
Sympathomimetic/stimulant agents (pseudoephedrine, amphetamines): Concomitant sympathomimetics may have additive pressor effects with bremelanotide, warranting blood pressure and heart rate monitoring during co-use.
PDE5 inhibitors (sildenafil, tadalafil): When used together, monitor cardiovascular status (blood pressure, symptoms) because combined central and peripheral actions can produce hemodynamic variability despite potential symptomatic synergy.

Avoid (3)

Uncontrolled hypertension or significant cardiovascular disease (ischemic heart disease, stroke history): Bremelanotide is contraindicated or should be used with extreme caution in patients with uncontrolled hypertension or significant cardiovascular disease due to risk of sustained blood pressure elevation and cardiovascular events.
Pregnancy and breastfeeding: Safety in pregnancy and lactation is not established, so bremelanotide should generally be avoided and alternative therapies considered for pregnant or breastfeeding patients.
Alpha‑adrenergic blockers and medications predisposing to orthostatic hypotension: Because bremelanotide can alter blood pressure and heart rate, agents that affect orthostatic tolerance should be evaluated carefully for risk of symptomatic hypotension or hemodynamic instability when combined.